| (Values in U.S. Thousands) | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 | Mar, 2018 |
| Sales | 0 | 0 | 0 | 3,350 | 2,920 |
| Sales Growth | unch | unch | -100.00% | +14.73% | +28.07% |
| Net Income | -290 | -330 | 5,450 | 330 | -200 |
| Net Income Growth | +12.12% | -106.06% | +1,551.51% | +265.00% | +60.78% |
Ekimas Corp (ASNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ADVANSOURCE BIOMATERIALS CORPORATION develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of disease states and anatomical sites. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company has developed CardioPass, a synthetic coronary bypass graft, which is currently in a clinical trial in Europe.